University of Southampton
Investigating the therapeutic potential of monoclonal antibodies targeting human GITR
Abstract
dc:description.abstractThe goal of this project was to investigate the immunomodulatory and anti-tumour activity of a<br/>series of novel monoclonal antibodies (mAbs) targeting human Glucocorticoid-induced TNFRrelated protein (GITR). GITR is a cell surface co-stimulatory receptor constitutively expressed at high<br/>levels on T regulatory cells (Tregs) and at low levels on naïve and memory T cells. Its activation<br/>results in the increased survival, proliferation and function of effector T cells as well as inhibiting<br/>the suppressive capacity of Tregs. GITR is therefore an attractive target for anti-tumour<br/>immunotherapies. To explore this, a panel of novel anti-human GITR mAbs were generated and<br/>investigated. To characterise these mAbs, both in-vitro and in-vivo methodologies were utilised.<br/>Surface plasmon resonance identified the binding affinities and binding domains of different<br/>antibody clones. Human GITR (hGITR) expressing Jurkat/NF-κB/GFP reporter cells were generated<br/>to understand how these mAbs influenced intracellular signalling pathways. Furthermore, CFSElabelled human peripheral blood mononuclear cells (PBMCs) were co-cultured with sub-optimal<br/>concentrations of anti-hCD3, alongside anti-hGITR mAbs, to determine the ability of anti-hGITR<br/>mAbs to modulate human T cell proliferation in-vitro. To investigate these mAbs in-vivo, a novel<br/>hGITR knock-in (hGITRKI) transgenic mouse was developed and characterised, followed by studies<br/>in mouse tumour models.<br/>The generated mAbs bound to either hGITR domain 1 or 2 with a range of affinities, with the<br/>majority increasing intracellular NF-κB. Two of the mAb clones reduced the proliferation of hCD3-<br/>stimulated T cells, demonstrating their ability to influence cellular function in human T cells in-vitro.<br/>However, this reduction was only observed when these clones were of the mIgG2a isotype, which<br/>suggested a potential mechanism of action through the mAb-mediated depletion of hGITR<br/>expressing T cells. In-vivo impacts were explored in newly generated hGITRKI mice. Insertion of the<br/>chimeric hGITR gene into exon 1 of the mGITR gene resulted in the simultaneous expression of cell<br/>surface hGITR as well as disruption of mGITR expression. Furthermore, hGITRKI mice displayed a<br/>hGITR expression pattern similar to that of human PBMCs. These mice were then used to determine<br/>the therapeutic efficacy of anti-hGITR mAbs in-vivo. One of the anti-hGITR mAbs (84-9 mIgG2a) was<br/>shown to reduce tumour size and increase survival in EG7-OVA tumour-bearing hGITRKI mice. This<br/>therapeutic benefit was dependent on antibody isotype. A potential mechanism of action was that<br/>84-9, in the mIgG2a format, depleted intratumoural Tregs which altered the ratio of effector to<br/>regulatory T cells within the tumour microenvironment. Future work will seek to further define<br/>mechanisms of action and the underlying properties that mediate its therapeutic activity in<br/>comparison to other mAbs directed to hGITR or other immune stimulatory receptors.
Degree
thesis:*- Name dc:type.qualificationname
- Ph.D.
- Level dc:type.qualificationlevel
- doctoral
- Grantor dc:publisher.institution
- University of Southampton
- Year dc:date.issued
- 2023
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Maguire, Shaun
- Advisors dc:contributor.advisor
-
- Cragg, Mark
- Willoughby, Jane
- ORCID person:identifier.orcid
Rights
- Language dc:language
- English, eng